Ikena Oncology, Inc. (NASDAQ:IKNA) Shares Sold by Peapod Lane Capital LLC

Peapod Lane Capital LLC cut its stake in shares of Ikena Oncology, Inc. (NASDAQ:IKNA - Free Report) by 41.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 296,437 shares of the company's stock after selling 211,431 shares during the period. Peapod Lane Capital LLC owned about 0.61% of Ikena Oncology worth $379,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its stake in shares of Ikena Oncology by 18,244.1% in the 4th quarter. JPMorgan Chase & Co. now owns 155,741 shares of the company's stock worth $255,000 after purchasing an additional 154,892 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Ikena Oncology by 21.0% during the fourth quarter. Geode Capital Management LLC now owns 327,962 shares of the company's stock worth $538,000 after acquiring an additional 56,936 shares during the last quarter. Gilead Sciences Inc. bought a new position in shares of Ikena Oncology during the fourth quarter worth $3,294,000. Northern Trust Corp boosted its position in shares of Ikena Oncology by 19.7% during the fourth quarter. Northern Trust Corp now owns 57,565 shares of the company's stock worth $94,000 after acquiring an additional 9,456 shares during the last quarter. Finally, BNP Paribas Financial Markets bought a new position in shares of Ikena Oncology during the fourth quarter worth $72,000. 75.00% of the stock is currently owned by hedge funds and other institutional investors.

Ikena Oncology Trading Down 2.2%

Shares of NASDAQ:IKNA traded down $0.03 during midday trading on Friday, reaching $1.36. 24,475 shares of the company were exchanged, compared to its average volume of 114,805. The business's fifty day moving average is $1.27 and its two-hundred day moving average is $1.34. Ikena Oncology, Inc. has a one year low of $0.97 and a one year high of $1.94. The stock has a market cap of $65.63 million, a PE ratio of -1.58 and a beta of 0.50.

Ikena Oncology (NASDAQ:IKNA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.03. As a group, sell-side analysts expect that Ikena Oncology, Inc. will post -0.91 EPS for the current year.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.